175 related articles for article (PubMed ID: 38519942)
1. Single-cell RNA sequencing integrated with bulk RNA sequencing analysis identifies a tumor immune microenvironment-related lncRNA signature in lung adenocarcinoma.
Ren Y; Wu R; Li C; Liu L; Li L; Weng S; Xu H; Xing Z; Zhang Y; Wang L; Liu Z; Han X
BMC Biol; 2024 Mar; 22(1):69. PubMed ID: 38519942
[TBL] [Abstract][Full Text] [Related]
2. Identification of an immune-related six-long noncoding RNA signature as a novel prognosis biomarker for adenocarcinoma of lung.
Miao H; Chen D; Li R; Hu J; Chen Y; Xu C; Wen Z
Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33324975
[TBL] [Abstract][Full Text] [Related]
3. H3K4me3-related lncRNAs signature and comprehensive analysis of H3K4me3 regulating tumor immunity in lung adenocarcinoma.
Fan T; Zhu M; Muhammad S; Xiao C; Li S; Tian H; Liu Y; Xue L; Zheng B; Li C; He J
Respir Res; 2023 May; 24(1):122. PubMed ID: 37131252
[TBL] [Abstract][Full Text] [Related]
4. Integrating bulk-RNA sequencing and single-cell sequencing analyses to characterize adenosine-enriched tumor microenvironment landscape and develop an adenosine-related prognostic signature predicting immunotherapy in lung adenocarcinoma.
Han T; Wu J; Liu Y; Zhou J; Miao R; Guo J; Xu Z; Xing Y; Bai Y; Hu D
Funct Integr Genomics; 2024 Jan; 24(1):19. PubMed ID: 38265702
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Analysis of Tumor Immune Microenvironment and Prognosis of m6A-Related IncRNAs in Lung Adenocarcinoma.
Shen Y; Hou N; Han F; Chen B; Shi J; Sun X
Crit Rev Eukaryot Gene Expr; 2022; 32(5):77-91. PubMed ID: 35993946
[TBL] [Abstract][Full Text] [Related]
6. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on B cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma.
Song P; Li W; Wu X; Qian Z; Ying J; Gao S; He J
Cancer Immunol Immunother; 2022 Oct; 71(10):2341-2354. PubMed ID: 35152302
[TBL] [Abstract][Full Text] [Related]
7. Immunogenic cell death-related long noncoding RNA influences immunotherapy against lung adenocarcinoma.
Sun D; Zhang C
Oncol Res; 2023; 31(5):753-767. PubMed ID: 37547766
[TBL] [Abstract][Full Text] [Related]
8. A disulfidptosis-related lncRNA signature for predicting prognosis and evaluating the tumor immune microenvironment of lung adenocarcinoma.
Song Z; Cao X; Wang X; Li Y; Zhang W; Wang Y; Chen L
Sci Rep; 2024 Feb; 14(1):4621. PubMed ID: 38409243
[TBL] [Abstract][Full Text] [Related]
9. Relapse-related long non-coding RNA signature to improve prognosis prediction of lung adenocarcinoma.
Zhou M; Xu W; Yue X; Zhao H; Wang Z; Shi H; Cheng L; Sun J
Oncotarget; 2016 May; 7(20):29720-38. PubMed ID: 27105492
[TBL] [Abstract][Full Text] [Related]
10. A Novel m6A-Related LncRNA Signature for Predicting Prognosis, Chemotherapy and Immunotherapy Response in Patients with Lung Adenocarcinoma.
Shen Y; Wang S; Wu Y
Cells; 2022 Aug; 11(15):. PubMed ID: 35954243
[TBL] [Abstract][Full Text] [Related]
11. Construction of RNA Methylation Modification-immune-related lncRNA Molecular Subtypes and Prognostic Scoring System in Lung Adenocarcinoma.
Wang J; Shu J
Curr Med Chem; 2024; 31(12):1539-1560. PubMed ID: 37680151
[TBL] [Abstract][Full Text] [Related]
12. Development and Validation of Lactate Metabolism-Related lncRNA Signature as a Prognostic Model for Lung Adenocarcinoma.
Mai S; Liang L; Mai G; Liu X; Diao D; Cai R; Liu L
Front Endocrinol (Lausanne); 2022; 13():829175. PubMed ID: 35422758
[TBL] [Abstract][Full Text] [Related]
13. Immune-related eight-lncRNA signature for improving prognosis prediction of lung adenocarcinoma.
Chen Y; Zhang X; Li J; Zhou M
J Clin Lab Anal; 2021 Nov; 35(11):e24018. PubMed ID: 34550610
[TBL] [Abstract][Full Text] [Related]
14. Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma.
Peng F; Wang R; Zhang Y; Zhao Z; Zhou W; Chang Z; Liang H; Zhao W; Qi L; Guo Z; Gu Y
Mol Cancer; 2017 Jun; 16(1):98. PubMed ID: 28587642
[TBL] [Abstract][Full Text] [Related]
15. Construction of an immune-related lncRNA signature as a novel prognosis biomarker for LUAD.
Chen H; Shen W; Ni S; Sang M; Wu S; Mu Y; Liu K; Li N; Zhu L; Xu G
Aging (Albany NY); 2021 Aug; 13(16):20684-20697. PubMed ID: 34438369
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the utility of an immune checkpoint-related lncRNA signature for identifying the prognosis and immunotherapy response of lung adenocarcinoma.
Zhang H; Liu M; Yang Z; Du G; Yu B; Gui Y; Cao L; Li X; Tan B
Sci Rep; 2022 Jul; 12(1):12785. PubMed ID: 35896612
[TBL] [Abstract][Full Text] [Related]
17. Characterization and validation of a ferroptosis-related LncRNA signature as a novel prognostic model for lung adenocarcinoma in tumor microenvironment.
Wang Y; Lu G; Xue X; Xie M; Wang Z; Ma Z; Feng Y; Shao C; Duan H; Pan M; Ding P; Li X; Han J; Yan X
Front Immunol; 2022; 13():903758. PubMed ID: 36016939
[TBL] [Abstract][Full Text] [Related]
18. A novel endoplasmic reticulum stress-related lncRNA signature for prognosis prediction and immune response evaluation in Stomach adenocarcinoma.
Song Z; Su M; Li X; Xie J; Han F; Yao J
BMC Gastroenterol; 2023 Dec; 23(1):432. PubMed ID: 38066437
[TBL] [Abstract][Full Text] [Related]
19. Integrated analysis of hypoxia-associated lncRNA signature to predict prognosis and immune microenvironment of lung adenocarcinoma patients.
Shao J; Zhang B; Kuai L; Li Q
Bioengineered; 2021 Dec; 12(1):6186-6200. PubMed ID: 34486476
[TBL] [Abstract][Full Text] [Related]
20. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
